📝 Kainova Therapeutic raises $23.5M

In partnership with

News of the Day

Kainova Therapeutic has successfully navigated a frigid 2026 fundraising environment to secure a $23.5 million Series B round. Led by new backer Investissement Québec, the round saw strong participation from a leading syndicate that included CTI Life Sciences Fund, Panacea Venture, and Schroders Capital. This capital injection pushes the company’s total venture funding to approximately $90 million USD, a war chest further bolstered by nearly $100 million USD in non-dilutive funding accumulated since its inception. The rebrand to Kainova, finalized just last month, signals a strategic maturation as the company accelerates its clinical-stage programs targeting the most complex "switchboards" of human biology.

If you have tweets you want to submit to be featured here (from you or someone you like), reply to this email with a link!

Chart of the Day